Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 13/20 | 0.57 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1130395 | 0.88 | IGF1R (0.54) | IGF1RARPIK3CATAS2R8 | |
| SCHEMBL1130931 | 0.84 | IGF1R (0.51) | IGF1RARPIK3CATAS2R8PIK3CD | |
| SCHEMBL1130160 | 0.83 | IGF1R (0.48) | IGF1RKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1129963 | 0.83 | IGF1R (0.49) | IGF1RARPIK3CATAS2R8 | |
| SCHEMBL1130711 | 0.83 | IGF1R (0.49) | IGF1RARPIK3CAKDM4EALDH1A1 | |
| SCHEMBL1130662 | 0.83 | IGF1R (0.49) | IGF1RARPIK3CATAS2R8 | |
| SCHEMBL1129830 | 0.83 | IGF1R (0.58) | IGF1RARTAS2R8KDM4EALDH1A1 | |
| SCHEMBL1130513 | 0.82 | IGF1R (0.49) | IGF1RARPIK3CAKDM4EALDH1A1 | |
| SCHEMBL1130034 | 0.82 | IGF1R (0.49) | IGF1RAR | |
| SCHEMBL1130519 | 0.82 | IGF1R (0.48) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | IGF1R 854/4885AR 2712/4885PIK3CA 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.